FILE PHOTO: U.S. President Donald Trump's Chief of Staff Susie Wiles looks on, at the White House, in Washington, U.S. February 3, 2025. REUTERS/Elizabeth Frantz/File Photo
The Daily Beast confirms that President Donald Trump’s abrupt passion to make the FDA approve vaping products came after a tobacco firm lobbied his office in each of the last four quarters, according to lobbying reports, either directly or through a firm where Chief of Staff Susie Wiles’ daughter works.
The DB reports Wiles was previously registered as a lobbyist for Ballard Partners, which lobbied the government on behalf of SI Group Client Services, an associated branch of U.S. international tobacco company Swisher. Wiles represented the tobacco firm in 2019, 2021, and 2022 and is “name-checked in filings at least once in each of those years,” says DB. She later lobbied Congress with Mercury Public Affairs, which also acted on behalf of SI Group in 2023 and 2024, according to Public Citizen.
“In the Swisher filings where she’s named, the most common lobbying issues were ‘Monitor FDA issues regarding flavoring in tobacco products’ and ‘FDA regulations,’” reports DB. “Since Wiles, 68, began working at the White House, Continental Strategy has lobbied consistently on behalf of Swisher.”
Katie Wiles was reportedly promoted by Continental the day after her mom was appointed White House chief of staff. She is now a partner in the firm but not a registered lobbyist.
Meanwhile, the Wall Street Journal reported on Tuesday that Trump scolded Food and Drug Administration commissioner Marty Makary for not moving fast enough to approve flavored vapes. The Journal reported that Trump’s advisers told him Makary had blocked his ambition to get those flavors approved, citing sources who said he and Trump, 79, had discussed them directly.
“Makary had reportedly pushed against the flavors because he was concerned about their appeal to children and possible public health risks,” reports DB.
“White House spokesperson Kush Desai said in a statement to the Beast: “President Trump consistently pledged to expand access to vapes in light of an abundance of evidence finding that these products are beneficial for Americans trying to quit smoking.
The FDA announced on Tuesday that it had given the thumbs-up to vape firm Glas to manufacture menthol, mango, and blueberry flavors.
Flavored vaping products have become a significant regulatory battleground, particularly regarding their appeal to youth. Public health organizations including the American Academy of Pediatrics have documented concerns that flavored vapes—especially fruity and dessert varieties—serve as gateway products for young people.
The FDA has previously restricted flavored e-cigarettes in certain contexts, citing youth addiction rates. However, the tobacco industry argues flavored products help adult smokers transition away from traditional cigarettes. The tension between these positions has intensified as vaping use among teenagers has fluctuated in recent years.
Makary's resistance to approving additional flavors aligns with FDA guidance emphasizing youth protection as a central regulatory concern. Trump's pressure to accelerate approvals represents a significant shift in FDA priorities, potentially prioritizing industry interests over the public health precautions that animated the agency's previous stance on flavor restrictions.